Balyasny Asset Management LLC Viridian Therapeutics, Inc.\De Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Balyasny Asset Management LLC holds 339,089 shares of VRDN stock, worth $6.76 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
339,089Holding current value
$6.76 Million% of portfolio
0.01%Shares
10 transactions
Others Institutions Holding VRDN
# of Institutions
181Shares Held
76.7MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$95.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$88.1 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$77.4 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$74.8 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$68.7 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $795M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...